Gudrun Stengel

Biography
Gudrun specializes in developing advanced genomics platforms, drawing on her experience in NGS development and background in biophysics and biochemistry. She has made significant contributions to the field, including the development of the NovaSeq platform at Illumina, and the Aviti platform at Element. In the startup space, she played a key role in securing Series B funding for Encodia through her work in proteomics. Currently, as the founder of Alida Biosciences, Gudrun is focused on creating novel RNA epitranscriptomic technologies designed to advance beyond primary transcriptomic sequence analysis, to empower a new frontier of RNA biology and enhancement of multi-omic studies.

---

Talk
RNA Beyond Primary Sequence: Introducing Multiplexed Epitranscriptomics
AlidaBios EpiPlex revolutionizes RNA modification profiling with high-throughput, multiplexed detection. Our approach integrates advanced library preparation with machine-learning powered bioinformatics and NGS readout, enabling quantifiable, scalable, and accessible multiomic insights. EpiPlex paves the way for personalized medicine by revealing disease-specific RNA modification patterns, making it a vital tool for precision health and multiomic studies.

Spatial Showcase:
Alida Biosciences
AlidaBio is commercializing accessible tools that broaden the application of epitranscriptomics in life sciences. Our groundbreaking products EpiPlex™ and EpiScout™ empower researchers to concurrently analyze multiple RNA modifications with relative quantification, using RNA inputs suitable for clinically relevant samples and supported by user-friendly bioinformatics.